JAMA Oncology: Derivation of Anthracycline and Anthraquinone Equivalence Ratios to Doxorubicin for Late-Onset Cardiotoxicity
January 31, 2019
Elizabeth A. M. Feijen, PhD1,2; Wendy M. Leisenring, ScD3,4; Kayla L. Stratton, MS3,4; Kirsten K. Ness, PT, PhD5; Helena J. H. van der Pal, MD, PhD2; Elvira C. van Dalen, MD, PhD1,2; Gregory T. Armstrong, MD, MSCE5; Gregory J. Aune, MD, PhD6; Daniel M. Green, MD5; Melissa M. Hudson, MD7; Jacqueline Loonen, MD, PhD8; Kevin C. Oeffinger, MD9; Leslie L. Robison, PhD5; Yutaka Yasui, PhD5; Leontien C. M. Kremer, MD, PhD1,2; Eric J. Chow, MD, MPH3,4,10 Abstract Importance Anthracyclines are part of many effective pediatric cancer treatment protocols. Most pediatric oncology treatment groups assume that the hematologic toxicity of anthracycline agents is equivalent […]